A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Inclusion Criteria:

- Must have a diagnosis of intra-ocular hypertension (raised IOP), or primary
open-angle glaucoma (POAG), with IOP >20 mmHg and ≤36 mmHg in the study eye, and is
currently prescribed a stable dose of a single anti-glaucoma medication that began at
least 30 days prior to the screening visit; OR

- Must have a diagnosis of intra-ocular hypertension (raised IOP), defined as an IOP
≥22 mmHg and ≤36 mmHg in the study eye while not on anti-glaucoma medication

- Male patients must be willing to use barrier contraception with spermicide, ie,
condoms, from the day of first dosing until 3 months after dosing with IP

- Placebo treatment for duration of the study must not be considered detrimental to the
patient

Exclusion Criteria:

- Have uncontrolled intra-ocular hypertension (>36 mmHg)

- Have experienced a significant visual field loss or showed evidence of progressive
visual field loss within the last year (as defined by >1 dB/yr average loss or vision
threatening new defect)

- Have had severe eye trauma at any time